Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Strategic Expansion into AI-Powered Healthcare Solutions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Daxor Corp DXR

Healthcare Medical Devices
Daxor Corporation is a blood volume measurement technology company, which is focused on blood volume testing innovation. The Company has developed and marketed the Blood Volume Analyzer (BVA-100), the diagnostic blood test cleared by the food and drug administration (FDA) to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific... see more

Recent & Breaking News (NDAQ:DXR)

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

GlobeNewswire March 1, 2022

Daxor Corporation Announces $1.35 Per Share NAV Increase and Files Annual Report for Fiscal 2021

GlobeNewswire March 1, 2022

Study Demonstrates Importance and Clinical Utility of Daxor's Blood Volume (BVA-100®) Diagnostic in the Assessment of Heart Failure

GlobeNewswire February 17, 2022

Daxor Corporation Commences Trading on The NASDAQ Capital Market

GlobeNewswire February 2, 2022

Caleb DesRosiers, JD, MPA Appointed to Daxor Corporation Board of Directors

GlobeNewswire January 21, 2022

Daxor Corporation to Commence Trading on The Nasdaq Capital Market On February 2, 2022

GlobeNewswire January 20, 2022

Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

GlobeNewswire January 6, 2022

DAXOR ANNOUNCES KEY MILESTONES ACHIEVED FOR MULTICENTER BVA-100® STUDY IN HOSPITALIZED PATIENTS WITH COVID-19

GlobeNewswire January 5, 2022

DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES

GlobeNewswire January 4, 2022

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting

GlobeNewswire November 16, 2021

New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100®) Diagnostic in Neurocritical Care

GlobeNewswire November 9, 2021

Daxor Corporation Receives $200K Matching Fund Award from Launch Tennessee

GlobeNewswire October 1, 2021

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting

GlobeNewswire September 14, 2021

Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100® Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021

GlobeNewswire September 8, 2021

Daxor Corporation to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

GlobeNewswire September 7, 2021

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

GlobeNewswire September 1, 2021

Daxor Corporation Reports a 26.5 Percent Rise in Diagnostic Sales Revenue in Form N-CSR Filing for the Six Months Ended June 30, 2021

GlobeNewswire August 30, 2021

Daxor's Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care

GlobeNewswire August 4, 2021

DAXOR CORPORATION ANNOUNCES NON-GOVERNMENT DISTRIBUTION AGREEMENT WITH CONCORDANCE® HEALTHCARE SOLUTIONS

GlobeNewswire July 22, 2021

American College of Cardiology (ACC) Features Expert Analysis on the Importance of Addressing Anemia With Blood Volume Analysis in Heart Failure Patients

GlobeNewswire July 13, 2021